Developments in the scientific and clinical understanding of the spondyloarthritides
Open Access
- 1 January 2009
- journal article
- review article
- Published by Springer Science and Business Media LLC in Arthritis Research & Therapy
- Vol. 11 (1), 208
- https://doi.org/10.1186/ar2562
Abstract
Major advances have been achieved over the last 10 years both in the clinical and scientific understanding of the spondyloarthritides (SpA), which can be separated in predominantly axial and predominantly peripheral SpA. The clinical progress includes the development of classification criteria, strategies for early diagnosis, definition of outcome criteria for clinical studies, and the conduction of a series of clinical studies with a focus on tumor necrosis factor (TNF) blockers. The proven high efficacy of TNF blocker treatment has meant a breakthrough for SpA patients, who until recently had only quite limited treatment options. More and more data have accumulated over recent years in regard to long-term efficacy and safety, prediction of response, and the relevance of extrarheumatic manifestations such as uveitis, psoriasis, and inflammatory bowel disease for treatment decisions with TNF blockers. A better understanding of the interaction of the immune system and inflammation with bone degradation/new bone formation is crucial for the development of optimal treatment strategies to prevent structural damage. Recent results from genetic studies could show that, besides HLA-B27, the interleukin-23 receptor and the ARTS1 enzyme are associated with ankylosing spondylitis. Only when the exact pathogenesis is clarified will a curative treatment be possible.Keywords
This publication has 58 references indexed in Scilit:
- Radiographic progression of ankylosing spondylitis after up to two years of treatment with etanerceptArthritis & Rheumatism, 2008
- Critical appraisal of assessment of structural damage in ankylosing spondylitis: Implications for treatment outcomesArthritis & Rheumatism, 2008
- Efficacy of sulfasalazine in patients with inflammatory back pain due to undifferentiated spondyloarthritis and early ankylosing spondylitis: a multicentre randomised controlled trialAnnals Of The Rheumatic Diseases, 2006
- Efficacy and safety of adalimumab in patients with ankylosing spondylitis: Results of a multicenter, randomized, double‐blind, placebo‐controlled trialArthritis & Rheumatism, 2006
- Concepts and epidemiology of spondyloarthritisBest Practice & Research Clinical Rheumatology, 2006
- Immunohistochemical analysis of hip arthritis in ankylosing spondylitis: Evaluation of the bone–cartilage interface and subchondral bone marrowArthritis & Rheumatism, 2006
- Systematic review of treatments for psoriatic arthritis: an evidence based approach and basis for treatment guidelines.2006
- Major reduction in spinal inflammation in patients with ankylosing spondylitis after treatment with infliximab: Results of a multicenter, randomized, double‐blind, placebo‐controlled magnetic resonance imaging studyArthritis & Rheumatism, 2006
- ASAS/EULAR recommendations for the management of ankylosing spondylitisAnnals Of The Rheumatic Diseases, 2006
- First update of the international ASAS consensus statement for the use of anti-TNF agents in patients with ankylosing spondylitisAnnals Of The Rheumatic Diseases, 2006